COVID-19 and cardiovascular disease
Clin Investig Arterioscler. 2020 Nov-Dec;32(6):263-266.
doi: 10.1016/j.arteri.2020.10.005.
[Article in
English,
Spanish]
Affiliation
- 1 Unidad de Medicina Interna. Consulta de Riesgo Vascular, Hospital Universitario Fundación Alcorcón. Universidad Rey Juan Carlos, c/ Budapest 1 28922, Madrid. Electronic address: cguijarro@fhalcorcon.es.
No abstract available
MeSH terms
-
Angiotensin-Converting Enzyme 2 / metabolism
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
COVID-19 / complications*
-
COVID-19 / epidemiology
-
COVID-19 Drug Treatment
-
Cardiovascular Diseases / etiology*
-
Cardiovascular Diseases / prevention & control
-
Endothelium, Vascular / physiology
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Pandemics
-
Risk Factors
-
SARS-CoV-2* / physiology
-
Spike Glycoprotein, Coronavirus / metabolism
-
Thrombosis / epidemiology
-
Thrombosis / etiology
-
Toll-Like Receptor 3 / metabolism
-
Virus Internalization
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Spike Glycoprotein, Coronavirus
-
TLR3 protein, human
-
Toll-Like Receptor 3
-
spike protein, SARS-CoV-2
-
Angiotensin-Converting Enzyme 2